Get started
ABBVIEABBVIEABBVIE

ABBVIE

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

4ABBV trade ideas

Technical indicators be damned, ABBV is going upAbbVie manufactures the anti-viral medication ritonavir , which is used to combat various viral infections, such as HIV and Hepatitis C. Ritonavir is also being used to treat the novel coronavirus. www.natap.org As the SARS II outbreak certainly worsens, ABBV might be one of the few stocks that survives the coming financial storm. A short term pullback is possible from the technical indicators but I don't think it will last long as virus cases increase exponentially.
NYSE:ABBVLong
by UnknownUnicorn6138131
ABBVAlright abbv has hit its first target..Now this DOENST mean this tops out the move..It can but its doesnt happen all the time so i dont use it that way..i use these targets to help me manage the trades. So were at the first target i put up a week ago or whatever its been now..so at target number one im taking between 25% and 50% of the position off and trail a stop up with the rest (for buying the outright stock)..for options there are many fancy things you can do..but the end goal is take something off the table and start managing and protecting the profits. target number 2 is the darker green line. At the second target if we get it ill take off another 30% of the position. So at the second target i should be out of 75% of the position with a little left to see how high is high for this trade. Always manage your trades
NYSE:ABBV
by Fibking95
Early Warning System Up, Price Down, News InterestingEWS Signal is outside of Std Dev of Root Mean Sq. Strong signal that the market has not responded to. Every other indicator on this stock is showing strong negative price projections. News on this stock indicating they may have the only potential treatment for Coronavirus already on the market. Kaletra is a protease inhibitor normally utilized in the treatment of HIV. Very speculative / high risk trade opportunity.
NYSE:ABBVLong
by StockSwinger
3
ABBV - Letting it Come in for a Better EntryOne of my absolute favorite stocks for the next 3 years: ABBV. I'm letting it come down a bit before initiating a position. My model says that there is going to be heavy buying between 74 and 79 which is where I will start accumulation. If you found this to be insightful or helpful, please show appreciation by hitting that like button. If you want more ideas I invite you to follow as well! I try to be here for all of my followers with any questions they might have. Feel free to shoot me a DM or comment below to start a conversation!
NYSE:ABBVLong
by chartsareforships
1
Dip buy with a coronaThe Beijing branch of China’s National Health Commission said a combination of lopinavir and ritonavir, sold under the brand name Kaletra by AbbVie, is part of its latest treatment plan for patients infected by the Coronavirus, which has killed at 81 people in China and sickened more than 2,800 worldwide. After breaking out of the downtrend, ABBV is coming back to retest the channel, support area and weekly 50 moving average. In terms of valuation, ABBV is currently trading at a Forward P/E ratio of 9. For comparison, its industry has an average Forward P/E of 15.48, which means ABBV is trading at a discount to the group. ABBV will be looking to display strength as it nears its next earnings release, which is expected to be February 7, 2020. In that report, analysts expect ABBV to post earnings of $2.20 per share. This would mark year-over-year growth of 15.79%
NYSE:ABBVLong
by Charlestrad3r
ABBV should soon find support for a bounceAbbvie has been falling hard on news that it will sell off some drug patents in order to win approval for its merger with Allergan. It is entering a support zone between about $77 and $81, however, and it may start to climb from here as investors start to get excited about the merger. Also look for Coronavirus news to move the stock; word on the street is that one of Abbvie's drugs is being used off-label to treat Coronavirus patients. With a 5.67% dividend yield and a forward P/E under 10, ABBV looks attractively valued. True, the patent sales will probably negatively affect that forward P/E, and the merger might ultimately result in a lower dividend yield. But Abbvie will also pocket a bunch of cash from those drug sales that can be used to grow its pipeline, and Allergan's forward P/E is also low, with plenty of potential upside.
NYSE:ABBVLong
by ChristopherCarrollSmith
2
Abbvie Inc set for revenue boost Shipments underway to China in the hope that the Coronavirus can be tackled by Abbvie's range of Antiviral drugs. Deep retrace had completed as has a bullish golden cross. The chart is not exactly bullish but fundamentals may dictate the next move. Above the 50 day moving average is a possible point of entry AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as as well as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
NYSE:ABBV
by Bullishcharts
ABBVIE bullish on new DealZURICH (Reuters) - U.S. drugmaker AbbVie's $63 billion tie-up with Allergan is getting help from Nestle and AstraZeneca buying up products the Irish-domiciled company is shedding to placate regulators. AbbVie is swallowing Allergan to give it control of the lucrative wrinkle treatment Botox and to diversify a portfolio heavily dependent on its $19-billion-per-year arthritis drug Humira, the world's best-selling medicine that is advancing toward U.S. patent expiration. Swiss food group Nestle bulked up its medical nutrition business with Allergan's Zenpep, a product with 2018 sales of $237 million which treats people whose pancreases do not provide enough enzymes to digest fats, proteins and sugars. Nestle did not give financial details, but analysts from Zuercher Kantonalbank estimated the takeover could have cost the Vevey, Switzerland-based company more than $1 billion. Meanwhile, AstraZeneca is regaining rights to brazikumab, Allergan's experimental drug against Crohn's Disease and ulcerative colitis. The European Commission said this month the immunology medicine must be divested because of the risk its development would be halted after AbbVie's takeover because of competing medicines. "These definitive agreements represent significant progress toward the completion of our acquisition of Allergan," Richard Gonzalez, AbbVie's chairman and chief executive, said. With regulators wary of the deal's anti-competitive potential, rivals are getting a chance to stock their own product shelves. Nestle Chief Executive Mark Schneider, who also gets Allergan's Viokace, another pancreatic enzyme product, in Monday's deal, is bulking up on nutrition products that combine properties of medicine and food as the Swiss company expands in areas where growth may outpace its mainstream food business. "This is a significant opportunity for our business in the United States," Greg Behar, head of Nestle Health Science, said in a statement. AstraZeneca's pact for brazikumab marks a return of the inflammation medicine to the British drugmaker's portfolio. In 2016, Astra had struck a licensing deal with Allergan worth up to $1.5 billion for the medicine. With its return to AstraZeneca, Allergan has agreed to fund development costs for brazikumab in Crohn's disease and ulcerative colitis, including the creation of a companion diagnostic, AstraZeneca said in a separate statement. "This agreement creates an opportunity for us to complete the full development program and bring this potential new treatment option to patients as quickly as possible," Mene Pangalos, Astra's biopharmaceuticals research head. Even if Allergan must foot the development bill, analysts appeared underwhelmed, in part because AbbVie's Skyrizi, or risankizumab, a similar medicine, has a head start. "This could be another autoimmune product to add to Astra's portfolio, although it will be somewhat late to the market," Liberum's Alistair Campbell wrote in a note to investors.
NYSE:ABBV
by RedHotStocks